ADR Biomedical Holdings Inc.
Notice Regarding Commencement of a New Business
Commencing a new business for the sale of pharmaceuticals and medical supplies. Scheduled to start in December 2026, and sales for the fiscal year ending March 2027 are expected to exceed the medium-term plan by approximately 350 million yen. No special initial investments are planned at this time.
Key Figures
- New business start timing: December 2026
- Expected sales contribution for fiscal year ending March 2027: to exceed by approx. 350 million yen
- Special expenditures: None planned at this time
AI要約
Overview of Business Commencement
Under the research and development framework for cell therapy and regenerative medicine centered on ADR Therapeutics, we will newly commence a sales business for pharmaceuticals and medical supplies. The target customers are medical institutions and clinics, and we plan to procure and sell pharmaceuticals and medical supplies from domestic and international manufacturers. The start timing is December 2026. No special expenditures are planned at this time.
Outlook and Impact
Regarding the impact on consolidated results for the fiscal year ending March 2027 due to the start of the new business, details are under review, but sales are expected to exceed the medium-term plan by approximately 350 million yen. Specific figures will be disclosed once calculated.
ADR Biomedical Holdings Inc.
Company overview · Stock price · Financial data · All IR